Cost-Effectiveness Model of Empiric Doripenem Compared with Imipenem-Cilastatin in Ventilator-Associated Pneumonia

Abstract

Given the current microbiologic sensitivity profile of PA to DOR and IMI, and depending on the local susceptibility patterns and in institutions where DOR in vitro susceptibilities are superior to those of other carbapenems for PA clinical isolates, empiric treatment of VAP with DOR may dominate that with IMI by being both life- and cost-saving.